Table 2 Univariate and multivariate analyses in patients treated with chemotherapy
Variables | EFS | OS | ||
|---|---|---|---|---|
HR (95% CI) | P-value | HR (95% CI) | P-value | |
Univariate analyses | ||||
 MiR-425 (high vs. low) | 0.449 (0.279–0.721) | 0.001 | 0.506 (0.316–0.811) | 0.005 |
 WBC (≥ 20 vs. < 20 × 109/L) | 0.939 (0.594–1.484) | 0.786 | 0.936 (0.591–1.484) | 0.779 |
 FLT3-ITD (positive vs. negative) | 1.242 (0.693–2.224) | 0.467 | 1.192 (0.665–2.136) | 0.555 |
 NPM1 (mutated vs. wild) | 1.168 (0.721–1.893) | 0.527 | 1.044 (0.640–1.704) | 0.862 |
 DNMT3A (mutated vs. wild) | 1.491 (0.909–2.446) | 0.114 | 1.432 (0.868–2.362) | 0.160 |
 RUNX1 (mutated vs. wild) | 1.464 (0.700–3.064) | 0.312 | 1.591 (0.759–3.335) | 0.219 |
 TP53 (mutated vs. wild) | 2.949 (1.510–7.561) | 0.002 | 2.898 (1.487–5.694) | 0.002 |
 CEBPA (mutated vs. wild) | 2.963 (0.910–9.648) | 0.071 | 2.901 (0.892–9.434) | 0.077 |
 IDHI/IDH2 (mutated vs. wild) | 1.006 (0.570–1.775) | 0.983 | 0.954 (0.532–1.710) | 0.874 |
 NRAS/KRAS (mutated vs. wild) | 1.143 (0.601–2.172) | 0.684 | 1.188 (0.625–2.260) | 0.599 |
 MLL-PTD (mutated vs. wild) | 0.836 (0.305–2.291) | 0.727 | 0.910 (0.332–2.495) | 0.855 |
Multivariate analyses | ||||
 MiR-425 (high vs. low) | 0.432 (0.266–0.703) | 0.001 | 0.502 (0.311–0.811) | 0.005 |
 FLT3-ITD (positive vs. negative) | 1.582 (0.868–2.883) | 0.134 | – | – |
 TP53 (mutated vs. wild) | 2.737 (1.377–5.438) | 0.004 | 2.519 (1.286–4.933) | 0.007 |
 CEBPA (mutated vs. wild) | 3.746 (1.102–12.736) | 0.034 | 3.228 (0.959–10.864) | 0.058 |